• Q1 2025 DAYBUE net sales of US$84.6 million, up 11% from Q1 2024
• Record number of unique patients received shipments, up 4% from Q4 2024
• Neuren's Q1 2025 royalty income was A$13.5 million, up 17% from Q1 2024

Neuren Pharmaceuticals reported highlights from the Q1 2025 financial results announcement and conference call of its partner Acadia Pharmaceuticals. Acadia announced Q1 2025 net sales of DAYBUE (trofinetide) in the United States (US) of US$84.6 million, up 11% on Q1 2024 and retained its full year 2025 US net sales guidance of US$380 - 405 million. The number of unique patients receiving a DAYBUE shipment reached a record high of 954 in Q1 2025, an increase of 4% from Q4 2024. Discontinuations were down 35% compared to Q4 2024 and down 66% compared with Q1 2024. The persistency rate remains steady above 50% at 12 months. 65% of active patients have now been on therapy for 12 months or longer. Acadia's full year 2025 DAYBUE net sales guidance is for the US only. Acadia is anticipating approval of the marketing application for Europe in Q1 2026 and continues to build EU leadership and launch teams. In the meantime, the first shipment of DAYBUE was made to a Rett syndrome patient in Germany in April under a managed access program. In Japan, trofinetide has now received Orphan Drug Designation and Acadia is on track to commence the planned clinical trial in Japan in Q3 2025. Acadia has also entered into distribution agreements to facilitate named patient supply in other regions including Latin America, Middle East and Asia Pacific. Neuren's anticipated royalties from DAYBUE sales are A$13.5 million for Q1 2025 and between A$62 million and A$67 million in the US for the full year 2025.

Acadia retained full year 2025 DAYBUE US net sales guidance of US$380 - 405 million, implying full year 2025 US royalty income for Neuren of A$62 - 67 million.

Acadia expects DAYBUE unique patients, volumes and net sales in the US to increase through 2025. There is substantial potential for future growth in the US with two-thirds of the 5,500 to 5,800 diagnosed Rett patients yet to try DAYBUE. Acadia has now completed expansion of its field force by ~30% to further accelerate growth.